• Something wrong with this record ?

Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients

L. Benesova, B. Belsanova, S. Suchanek, M. Kopeckova, P. Minarikova, L. Lipska, M. Levy, V. Visokai, M. Zavoral, M. Minarik,

. 2013 ; 433 (2) : 227-34.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Prognosis of solid cancers is generally more favorable if the disease is treated early and efficiently. A key to long cancer survival is in radical surgical therapy directed at the primary tumor followed by early detection of possible progression, with swift application of subsequent therapeutic intervention reducing the risk of disease generalization. The conventional follow-up care is based on regular observation of tumor markers in combination with computed tomography/endoscopic ultrasound/magnetic resonance/positron emission tomography imaging to monitor potential tumor progression. A recent development in methodologies allowing screening for a presence of cell-free DNA (cfDNA) brings a new viable tool in early detection and management of major cancers. It is believed that cfDNA is released from tumors primarily due to necrotization, whereas the origin of nontumorous cfDNA is mostly apoptotic. The process of cfDNA detection starts with proper collection and treatment of blood and isolation and storage of blood plasma. The next important steps include cfDNA extraction from plasma and its detection and/or quantification. To distinguish tumor cfDNA from nontumorous cfDNA, specific somatic DNA mutations, previously localized in the primary tumor tissue, are identified in the extracted cfDNA. Apart from conventional mutation detection approaches, several dedicated techniques have been presented to detect low levels of cfDNA in an excess of nontumorous (nonmutated) DNA, including real-time polymerase chain reaction (PCR), "BEAMing" (beads, emulsion, amplification, and magnetics), and denaturing capillary electrophoresis. Techniques to facilitate the mutant detection, such as mutant-enriched PCR and COLD-PCR (coamplification at lower denaturation temperature PCR), are also applicable. Finally, a number of newly developed miniaturized approaches, such as single-molecule sequencing, are promising for the future.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024398
003      
CZ-PrNML
005      
20170615144740.0
007      
ta
008      
130703s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ab.2012.06.018 $2 doi
035    __
$a (PubMed)22750103
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Benesova, L $u Laboratory of Molecular Genetics and Oncology, Genomac Research Institute, 155 41 Prague, Czech Republic.
245    10
$a Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients / $c L. Benesova, B. Belsanova, S. Suchanek, M. Kopeckova, P. Minarikova, L. Lipska, M. Levy, V. Visokai, M. Zavoral, M. Minarik,
520    9_
$a Prognosis of solid cancers is generally more favorable if the disease is treated early and efficiently. A key to long cancer survival is in radical surgical therapy directed at the primary tumor followed by early detection of possible progression, with swift application of subsequent therapeutic intervention reducing the risk of disease generalization. The conventional follow-up care is based on regular observation of tumor markers in combination with computed tomography/endoscopic ultrasound/magnetic resonance/positron emission tomography imaging to monitor potential tumor progression. A recent development in methodologies allowing screening for a presence of cell-free DNA (cfDNA) brings a new viable tool in early detection and management of major cancers. It is believed that cfDNA is released from tumors primarily due to necrotization, whereas the origin of nontumorous cfDNA is mostly apoptotic. The process of cfDNA detection starts with proper collection and treatment of blood and isolation and storage of blood plasma. The next important steps include cfDNA extraction from plasma and its detection and/or quantification. To distinguish tumor cfDNA from nontumorous cfDNA, specific somatic DNA mutations, previously localized in the primary tumor tissue, are identified in the extracted cfDNA. Apart from conventional mutation detection approaches, several dedicated techniques have been presented to detect low levels of cfDNA in an excess of nontumorous (nonmutated) DNA, including real-time polymerase chain reaction (PCR), "BEAMing" (beads, emulsion, amplification, and magnetics), and denaturing capillary electrophoresis. Techniques to facilitate the mutant detection, such as mutant-enriched PCR and COLD-PCR (coamplification at lower denaturation temperature PCR), are also applicable. Finally, a number of newly developed miniaturized approaches, such as single-molecule sequencing, are promising for the future.
650    _2
$a zvířata $7 D000818
650    12
$a apoptóza $7 D017209
650    _2
$a mutační analýza DNA $x přístrojové vybavení $x metody $7 D004252
650    _2
$a DNA nádorová $x krev $x genetika $7 D004273
650    _2
$a lidé $7 D006801
650    12
$a mutace $7 D009154
650    _2
$a nekróza $7 D009336
650    _2
$a nádory $x krev $x genetika $x patologie $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Belsanova, B $u -
700    1_
$a Suchánek, Štěpán $7 xx0105313
700    1_
$a Kopeckova, M $u -
700    1_
$a Minarikova, P $u -
700    1_
$a Lipska, L $u -
700    1_
$a Levy, M $u -
700    1_
$a Visokai, V $u -
700    1_
$a Zavoral, Miroslav, $d 1953- $7 xx0036686
700    1_
$a Minarik, M $u -
773    0_
$w MED00000335 $t Analytical biochemistry $x 1096-0309 $g Roč. 433, č. 2 (2013), s. 227-34
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22750103 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20170615145155 $b ABA008
999    __
$a ok $b bmc $g 988078 $s 822778
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 433 $c 2 $d 227-34 $i 1096-0309 $m Analytical biochemistry $n Anal Biochem $x MED00000335
LZP    __
$a Pubmed-20130703

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...